These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 37634130)
1. Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. Joosten LPT; van Doorn S; van de Ven PM; Köhlen BTG; Nierman MC; Koek HL; Hemels MEW; Huisman MV; Kruip M; Faber LM; Wiersma NM; Buding WF; Fijnheer R; Adriaansen HJ; Roes KC; Hoes AW; Rutten FH; Geersing GJ Circulation; 2024 Jan; 149(4):279-289. PubMed ID: 37634130 [TBL] [Abstract][Full Text] [Related]
2. Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial. Joosten LPT; van Doorn S; Hoes AW; Nierman MC; Wiersma NM; Koek HL; Hemels MEW; Huisman MV; Roes KC; van den Bor RM; Buding WF; Rutten FH; Geersing GJ BMJ Open; 2019 Dec; 9(12):e032488. PubMed ID: 31888928 [TBL] [Abstract][Full Text] [Related]
3. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115 [TBL] [Abstract][Full Text] [Related]
4. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. De Caterina R; John Camm A Europace; 2016 Jan; 18(1):6-11. PubMed ID: 26450845 [TBL] [Abstract][Full Text] [Related]
5. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry. Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496 [TBL] [Abstract][Full Text] [Related]
6. Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation. Hellfritzsch M; Grove EL; Husted SE; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A Europace; 2017 Jul; 19(7):1091-1095. PubMed ID: 28641379 [TBL] [Abstract][Full Text] [Related]
7. [Coumarin or DOAC in frail elderly patients with atrial fibrillation?]. Joosten LPT; van Doorn S; Hemels MEW; Huisman MV; Rutten FH; Geersing GJ Ned Tijdschr Geneeskd; 2024 Jan; 168():. PubMed ID: 38525862 [TBL] [Abstract][Full Text] [Related]
8. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial. Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805 [TBL] [Abstract][Full Text] [Related]
9. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation. Vinding NE; Bonde AN; Rørth R; Lamberts M; Olesen JB; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL Europace; 2019 Apr; 21(4):572-580. PubMed ID: 30508073 [TBL] [Abstract][Full Text] [Related]
10. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends. Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389 [TBL] [Abstract][Full Text] [Related]
11. New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience. Gorczyca-Michta I; Wożakowska-Kapłon B Kardiol Pol; 2015; 73(2):85-93. PubMed ID: 25179482 [TBL] [Abstract][Full Text] [Related]
12. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study. Reinecke H; Engelbertz C; Bauersachs R; Breithardt G; Echterhoff HH; Gerß J; Haeusler KG; Hewing B; Hoyer J; Juergensmeyer S; Klingenheben T; Knapp G; Christian Rump L; Schmidt-Guertler H; Wanner C; Kirchhof P; Goerlich D Circulation; 2023 Jan; 147(4):296-309. PubMed ID: 36335915 [TBL] [Abstract][Full Text] [Related]
14. Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. Patti G; Pecen L; Lucerna M; Huber K; Rohla M; Renda G; Siller-Matula J; Ricci F; Kirchhof P; De Caterina R Am J Med; 2019 Jun; 132(6):749-757.e5. PubMed ID: 30664837 [TBL] [Abstract][Full Text] [Related]
15. In older patients with AF and frailty, switching from VKA to NOAC therapy increased a composite of major or CRNM bleeding at 12 mo. Dunn A Ann Intern Med; 2024 May; 177(5):JC57. PubMed ID: 38710082 [TBL] [Abstract][Full Text] [Related]
16. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Bouillon K; Bertrand M; Maura G; Blotière PO; Ricordeau P; Zureik M Lancet Haematol; 2015 Apr; 2(4):e150-9. PubMed ID: 26687957 [TBL] [Abstract][Full Text] [Related]
17. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves. Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338 [TBL] [Abstract][Full Text] [Related]
19. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]